Cue Biopharma, Inc. (CUE) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 9 Buy.
The consensus price target is $4.33 (low: $2.00, high: $7.00), representing an upside of 888.6% from the current price $0.44.
Analysts estimate Earnings Per Share (EPS) of $-0.74 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.72 vs est $-0.74 (beat +2.2%). 2025: actual $-0.28 vs est $-0.40 (beat +30%). Analyst accuracy: 77%.
CUE Stock — 12-Month Price Forecast
$4.33
▲ +888.58% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Cue Biopharma, Inc., the average price target is $4.33, with a high forecast of $7.00, and a low forecast of $2.00.
The average price target represents a +888.58% change from the last price of $0.44.
Highest Price Target
$7.00
Average Price Target
$4.33
Lowest Price Target
$2.00
CUE Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Cue Biopharma, Inc. in the past 3 months
EPS Estimates — CUE
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.72
vs Est –$0.74
▲ 2.2% off
2025
Actual –$0.28
vs Est –$0.40
▲ 42.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CUE
61%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.009B
vs Est $0.009B
▼ 1.3% off
2025
Actual $0.027B
vs Est $0.007B
▲ 76.3% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
